top of page
BioVolume 3D Subcutaneous tumour imaging


Advancing preclinical oncology with thermography and 3D scanning of subcutaneous tumours.

BioVolume 3D tumour model

BioVolume is the world’s first 3D imaging solution that has been developed in partnership with a leading pharmaceutical company and wider industry for visualising and measuring subcutaneous tumour growth in preclinical oncology research.

BioVolume  was conceived to enable faster, smarter and more confident decisions to be made in the identification and development of new cancer therapeutics.

By using a measurement device with lower user variability, the chance of missing a therapeutic effect can be reduced and time and resources spent pursuing false results can be saved.

Reduce the chance of missing
a therapeutic effect
by up to
for a 650mm3 difference between treatment groups,
when compared to calliper user characteristics
Read the peer reviewed paper In Cancer Informatics:

In Silico Modeling Demonstrates that User Variability During Tumor Measurement Can Affect In Vivo Therapeutic Efficacy Outcomes
Used by leading pharma, biotech and research institutions including:

“After purchasing the unit, it is now being used daily scanning on average 6 different protocols, saving us 30-60 minutes every day. BioVolume has lessened the error in tumor measurement and it has helped significantly in recognizing when the tumor has fully taken to the mouse rather than it being Matrigel.”


Emily McLure, Research Associate II/ Research Animal Lab Manager, Orano med


BioVolume enables cancer research companies to obtain more accurate, repeatable data than before. Translational science is also improved through data reliability and transparency.

BioVolume repeatability


By significantly reducing

inter-operator variability across studies BioVolume can improve repeatability, removing the reliance on a single operator to complete a study.

BioVolume scientific confidence


With 3D imaging and thermography of each rodent tumour 
BioVolume's algorithmic
approach to segmentation
and measurement ensures
consistency in output.

BioVolume traceability


BioVolume's secure cloud-based platform ensures all data is a captured, secured and available for review, offering full transparency in study data collection and analysis.  

How it works

BioVolume uses proprietary capture analysis technologies to scan rodent tumours, recording RGB, thermal and 3D model data, delivering automatic detection, segmentation and measurement of a tumour’s volume. The data is processed and stored on the BioVolume cloud, allowing for a fast capture workflow and incorporates a fully traceable data storage and output solution for detailed analysis.

BioVolume 3D tumour model



BioVolume platform overview


BioVolume was designed with the user's workflow in mind, ensuring that a measurement session can be completed as quickly as with callipers but with all the benefits of an advanced imaging platform. 

BioVolume 3D and Thermal scanner
The science




In this experiment 3 operators at the Genomics Institute of the Novartis Research Foundation (GNF) were tasked with capturing measurements of subcutaneous tumours on mice with both callipers and BioVolume on the same day, for the duration of the study protocol. 


This was then repeated over 2 further experiments (3 experiments in total). The primary goal was to compare the inter operator variability of the 2 techniques to see if BioVolume outperformed callipers in the repeatability of measurements between operators. 


A secondary goal of the experiment was to see if collecting image data (thermal,  3D and RGB photographic image sets) using BioVolume provided additional traceability benefits to the operators.  


3 Operators anonymised with labels 101, 102 and 103, were chosen at random to take measurements of single subcutaneous tumours implanted on the flank of 40 C57 Black/6 mice. 


The experiment was conducted on 2 further studies containing 64 and 32 mice respectively, this time on Balb/C mice. 

2 different techniques were used for measurement during this standard tumour growth study (with no compound or dosing of the animals).

Study Type
Study Duration
12 days after implantation
Measurement frequency
Twice weekly
Page 1 of 2


BioVolume growth curve experimental output

Fig. 1


After all of the data was collected, growth curves were plotted for both BioVolume and calliper tumour volume measurements obtained by the 3 operators.

The results can be seen in Fig. 1, and visually demonstrates reduced variability between users during the initial study, when utilising BioVolume.


Intra-class correlation analysis is used to assess the variance across operators whilst accounting for other sources of variation. High ICC corresponds to high agreement
(1 is perfect agreement). 

For the 3 experiments, there is a statistically significant difference between the 2 techniques. The BioVolume ICC score is in the ‘excellent’ group, while the result for callipers falls into the ‘good/moderate’ group.

BioVolume ICC inter-operator variability performance

BioVolume ICC: 0.96 (0.95- 0.96)
Category: Excellent 



Callipers: 0.86 (0.73 - 0.91)
Category: Good/ Moderate

ICC plot key
BioVolume traceable growth


BioVolume records 3D models, RGB and thermal imagery for each rodent measurement, allowing interrogation at an individual rodent level. Tumour progression can be tracked visually, providing confidence in measurement output.


ICC and CoV analysis show statistically significant improvement in inter-operator variability across all 3 users when utilising BioVolume within the three individual experiments. This allows us to conclude that BioVolume can offer an improvement in study repeatability, as well as additional associated benefits.

The secondary goal of determining whether the collection of image data provided the user with additional benefits by way of allowing interrogation of raw data was also found to be true. BioVolume’s thermal, 3D and RGB image sets provided traceable visualisations of physical tumour growth over time, resulting in greater user confidence of the study outcome.


Explore the latest publications and news about BioVolume. 

Trends in Subcutaneous Tumour Height and Impact on Measurement Accuracy

5/2/23, 1:59 PM

When tracking tumour growth over time, important morphological information and measurement accuracy is lost by ignoring height.

In Silico Modeling Demonstrates that User Variability During Tumor Measurement Can Affect In Vivo Efficacy Outcomes

12/6/22, 11:44 AM

User measurement bias is a source of variation in preclinical studies. We investigated if variability could impact outcomes, using false negative result rate when comparing treated and control groups.

BioVolume Feature Updates September 2022

9/9/22, 11:29 AM

Info on our major release. New features include tumour condition area, multi-site measurement and a new randomisation tool.

TransCure bioServices offers BioVolume 3D imaging for insightful preclinical oncology research

2/6/23, 4:07 PM

Read the BioPharma article where Dr Sébastien Tabruyn, General Manager and Chief Scientific Officer, TransCure bioServices discusses why they are now offering BioVolume to their clients.

Modelling the cost impact of creating greater preclinical reproducibility through digitization

11/14/22, 11:58 AM

Poster presented at AALAS 2022 exploring how digitizing preclinical processes within efficacy testing, has the potential to reduce the cost of drug development by $39 million.

BioVolume Feature Updates August 2022

8/5/22, 7:09 AM

The releases and updates made this year and a quick look at what’s to come in a major release this August.

Comparing Variability in Measurement of Subcutaneous Tumors in Mice Using 3D Thermal Imaging and Calipers

1/4/23, 11:44 AM

Download our publication in JAALAS Comparative Medicine investigating how variability can be reduced in the measurement of Subcutaneous Tumors in Mice when using 3D Thermal Imaging

Measurement of subcutaneous tumor height achieves greater volumetric accuracy

11/14/22, 11:58 AM

Poster presented at AALAS 2022 highlighting the need to capture tumor height for more accurate volumes.

Whitepaper: Modelling the economic impact of improving preclinical reproducibility with BioVolume

6/28/22, 7:48 AM

This report demonstrates how adopting BioVolume could save up to $38m in the drug development cycle, utilising the economic model created by Paul et al in their 2010 analysis.

News & Publications


Every BioVolume implementation is delivered as a complete service package including hardware, software, platform, training and support. 







H: 198mm

BioVolume scanner technical drawing

W: 169mm

L: 278mm

BioVolume system


Aperture plate 


Dust cover


Scan capture button


USB-B port